Trending News Today: Revised Screening Guidelines Could Miss Cases of Cervical Cancer

Recently, President Donald Trump announced plans to sign an executive order that would allow individuals to purchase health insurance across state lines. However, legal experts said this order will likely be challenged in court because it may violate federal laws that regulate employee benefit plans, according to The New York Times. Although exact details have yet to be released, the order will likely seek ways for individuals and small businesses to purchase large group plans. Healthcare analysts report that this would allow Americans to obtain low-cost, low-value insurance, which could threaten the Affordable Care Act marketplace, according to the Times.

Researchers and patient advocates have voiced concerns that relaxing guidelines for cervical cancer screenings may not detect cases of the disease, especially among minority women, according to NPR. In September, the US Preventive Services Task Force issued a draft recommendation that women aged 30 to 64 years should receive a Pap test every 3 years or a human papillomavirus test every 5 years. Current guidelines recommend that these women receive both tests every 5 years. CDC data indicates that Latina and black women are the most likely group to develop cervical cancer. By limiting access to co-testing, advocates fear that many women—especially minority women—would experience an increase in the rate of cervical cancers that could be detected early with screening, according to the article.

Despite warnings from physicians and health organizations, modifiable risk factors are still causing strokes among all age groups and ethnicities, according to NPR. The authors of a new study published by Neurology found that more than 80% of first strokes were related to modifiable or preventable risk factors, including high cholesterol, smoking, illicit drug use, unhealthy diet, sedentary lifestyle, and diabetes. The rate of diabetes among stroke patients was alarmingly high, with 50% of Hispanic patients and 44% of African American patients having the condition, according to the article. The authors urge healthcare providers to look closely at these populations. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.